BACKGROUND: Urinary tract symptoms are an underestimated problem in multiple sclerosis (MS). OBJECTIVE: Hundred urodynamics of MS patients have been evaluated prospectively. DESIGN, SETTING AND PARTICIPANTS: In an inpatient rehabilitation, all persons with MS who also suffered from urinary tract symptoms received a voiding diary, post-void sonography and an urodynamic examination according to International Continence-Society-Standard. RESULTS AND LIMITATIONS: Between 10/2009 and 3/2011, 100 patients (79 women; 21 men; mean EDSS, 4.52 ± 2.26) were examined who had primary progressive MS (9×), relapsing-remitting MS (41×), secondary progressive MS (43×) and CIS (1×). The mean duration of MS was 10.26 ± 10.09 years and mean duration of LUTS, 6.9 ± 7.75 years. Urodynamic testing showed normal findings in 22 patients, detrusor overactivity in 7, increased bladder sensation without detrusor overactivity in 21, detrusor-sphincter dyssynergia in 26, detrusor hypocontractility in 12, detrusor acontractility in 4 and unclear diagnosis in 8 patients. Statistically significant risk factors for pathological urodynamic findings were as follows: wheelchair dependency, use of more than one incontinence pad per day and a MS type other than relapsing-remitting. CONCLUSIONS: The urodynamic investigation at hand showed urinary tract dysfunction in 78 of 100 MS patients with lower urinary tract symptoms (LUTS). The long latency between the occurrence of MS and/or the beginning of LUTS and the first neuro-urological evaluation indicates a deficit in treatment. Beyond national guidelines, all MS patients should at regular intervals be questioned about LUTS and receive urodynamic assessment especially according to the presented risk profile.
BACKGROUND: Urinary tract symptoms are an underestimated problem in multiple sclerosis (MS). OBJECTIVE: Hundred urodynamics of MS patients have been evaluated prospectively. DESIGN, SETTING AND PARTICIPANTS: In an inpatient rehabilitation, all persons with MS who also suffered from urinary tract symptoms received a voiding diary, post-void sonography and an urodynamic examination according to International Continence-Society-Standard. RESULTS AND LIMITATIONS: Between 10/2009 and 3/2011, 100 patients (79 women; 21 men; mean EDSS, 4.52 ± 2.26) were examined who had primary progressive MS (9×), relapsing-remitting MS (41×), secondary progressive MS (43×) and CIS (1×). The mean duration of MS was 10.26 ± 10.09 years and mean duration of LUTS, 6.9 ± 7.75 years. Urodynamic testing showed normal findings in 22 patients, detrusor overactivity in 7, increased bladder sensation without detrusor overactivity in 21, detrusor-sphincter dyssynergia in 26, detrusor hypocontractility in 12, detrusor acontractility in 4 and unclear diagnosis in 8 patients. Statistically significant risk factors for pathological urodynamic findings were as follows: wheelchair dependency, use of more than one incontinence pad per day and a MS type other than relapsing-remitting. CONCLUSIONS: The urodynamic investigation at hand showed urinary tract dysfunction in 78 of 100 MS patients with lower urinary tract symptoms (LUTS). The long latency between the occurrence of MS and/or the beginning of LUTS and the first neuro-urological evaluation indicates a deficit in treatment. Beyond national guidelines, all MS patients should at regular intervals be questioned about LUTS and receive urodynamic assessment especially according to the presented risk profile.
Authors: Werner Schäfer; Paul Abrams; Limin Liao; Anders Mattiasson; Francesco Pesce; Anders Spangberg; Arthur M Sterling; Norman R Zinner; Philip van Kerrebroeck Journal: Neurourol Urodyn Date: 2002 Impact factor: 2.696
Authors: Sarah-Michelle Orton; Sreeram V Ramagopalan; Andrea E Para; Mathew R Lincoln; Lahiru Handunnetthi; Michael J Chao; Julia Morahan; Katie M Morrison; A Dessa Sadovnick; George C Ebers Journal: J Neurol Sci Date: 2011-03-26 Impact factor: 3.181
Authors: A Giannantoni; G Scivoletto; S M Di Stasi; M G Grasso; E Finazzi Agrò; G Collura; G Vespasiani Journal: Arch Phys Med Rehabil Date: 1999-04 Impact factor: 3.966
Authors: W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky Journal: Ann Neurol Date: 2001-07 Impact factor: 10.422
Authors: André Luiz Farinhas Tomé; Eduardo P Miranda; José de Bessa Júnior; Carlos Alberto Bezerra; Antônio Carlos Lima Pompeo; Sidney Glina; Cristiano Mendes Gomes Journal: Clinics (Sao Paulo) Date: 2019-03-14 Impact factor: 2.365
Authors: Burkhard Domurath; Peter Flachenecker; Thomas Henze; Wolfgang Feneberg; Anna Brandt; Ines Kurze; Ruth Kirschner-Hermanns; Albert Kaufmann; Jörn Bremer; Manuela Vonthien; Kerstin Ratering; Christoph Schäfer; Will Nelson Vance; Paul Schmidt Journal: Nervenarzt Date: 2021-01-05 Impact factor: 1.214
Authors: Janina Beck; Anke Kirsten Jaekel; Federico Leopoldo Zeller; Michael Kowollik; Ines Kurze; Albert Kaufmann; Wolfgang Feneberg; Anna Brandt; Peter Flachenecker; Thomas Henze; Burkhard Domurath; Paul Schmidt; Will Nelson Vance; Franziska Goldschmidt; Ruth Klara Maria Kirschner-Hermanns; Stephanie C Knüpfer Journal: Diagnostics (Basel) Date: 2022-01-13